Roles of heparan-sulphate glycosaminoglycans in cancer

Nature Reviews Cancer

Volumn 2, Issue 7, 2002, Pages 521-528

  Sasisekharan, Ram ^a,b   Shriver, Zachary ^a   Venkataraman, Ganesh ^a   Narayanasami, Uma ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; HEPARANASE; HEPARIN; POLYSACCHARIDE; PROTEOHEPARAN SULFATE; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; GLUCURONIC ACID; GLYCOSAMINOGLYCAN; GLYPICAN; HEPARAN SULFATE; HEPARIN DERIVATIVE; IDURONIC ACID; INTERLEUKIN 8; LAMININ; LOW MOLECULAR WEIGHT HEPARIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OLIGOSACCHARIDE; PADGEM PROTEIN; PERLECAN; SCATTER FACTOR; SYNDECAN; THROMBIN; THROMBOPLASTIN; VASCULOTROPIN;

ANIMAL; CELL MEMBRANE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION; ANGIOGENESIS; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL SURFACE; EXTRACELLULAR MATRIX; IMMUNOMODULATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL MEMBRANE; GLUCURONIDASE; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; NEOPLASMS; POLYSACCHARIDES; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036637267     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc842     Document Type: Article

References (67)

1. Perrimon, N. &Bernfield, M.: Specificities of heparan sulphate proteoglycans in developmental processes.Nature404, 725-728 (2000).
2. Conrad, H. E.:Heparin-Binding Proteins(Academic Press, San Diego, 1998).
3. Conrad, H. E.:This book describes what is known about the structure and function of HSGAGs, as well as toolsthat have been developed to study structure-functionrelationships.
4. Liu, D., Shriver, Z., Qi, Y., Venkataraman, G. &Sasisekharan, R.: Dynamic regulation of tumor growth and metastasis byheparan sulfate glycosaminoglycans.Semin. Thromb.Hemost.28, 67-78 (2002).
5. Gallagher, J. T.: Heparan sulfate: growth control with a restricted sequence menu.J. Clin. Invest.108, 357-361 (2001).
6. Esko, J. D. &Lindahl, U.: Molecular diversity of heparan sulfate.J. Clin. Invest.108, 169-173 (2001).
7. Turnbull, J., Powell, A. &Guimond, S.: Heparan sulfate: decoding a dynamic multifunctional cell regulator.TrendsCell Biol.11, 75-82 (2001).
8. Sasisekharan, R. &Venkataraman, G.: Heparin and heparan sulfate: biosynthesis, structure and function.Curr. Opin.Chem. Biol.4, 626-631 (2000).
9. Faham, S., Linhardt, R. J. &Rees, D. C.: Diversity does make a difference: fibroblast growth factor-heparininteractions.Curr. Opin. Struct. Biol.8, 578-586 (1998).
10. Jin, L.:The anticoagulant activation of antithrombin byheparin.Proc. Natl Acad. Sci. USA94, 14683-14688 (1997).
11. Schlessinger, J.:Crystal structure of a ternaryFGF-FGFR-heparin complex reveals a dual role for heparinin FGFR binding and dimerization.Mol. Cell 6, 743-750(2000).
12. DiGabriele, A. D.:Structure of a heparin-linked biologically active dimer of fibroblast growth factor.Nature393, 812-817 (1998).
13. Mulloy, B. &Linhardt, R. J.: Order out of complexity: protein structures that interact with heparin.Curr. Opin. Struct. Biol.11, 623-628 (2001).
14. Chang, Z., Meyer, K., Rapraeger, A. C. &Friedl, A.: Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complexin situ. FASEB J.14, 137-144 (2000).
15. Nurcombe, V., Ford, M. D., Wildschut, J. A. &Bartlett, P. F.: Developmental regulation of neural response to FGF1 andFGF2 by heparan sulfate proteoglycan.Science 260, 103-106 (1993).
16. Dhoot, G. K.:Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase.Science 293, 1663-1666 (2001).
17. Dhoot, G. K.:Shows that cells actively modulate their HSGAG coat to influence morphogen gradients and, Therefore, pattern formation.
18. Cosgrove, R. H., Zacharski, L. R., Racine, E. &Andersen, J. C.: Improved cancer mortality with low-molecular-weightheparin treatment: a review of the evidence.Semin. Thromb.Hemost.28, 79-88 (2002).
19. Vlodavsky, I. &Friedmann, Y.: Molecular properties and involvement of heparanase in cancer metastasis andangiogenesis.J. Clin. Invest.108, 341-347 (2001).
20. Varki, N. M. &Varki, A.: Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies inhumans.Semin. Thromb. Hemost.28, 53-66(2002).
21. Liu, D., Shriver, Z., Venkataraman, G., El Shabrawi, Y. &Sasisekharan, R.: Tumor cell surface heparan sulfate ascryptic promoters or inhibitors of tumor growth andmetastasis.Proc. Natl Acad. Sci. USA99, 568-573(2002).
22. Liu, D., Shriver, Z., Venkataraman, G., El Shabrawi, Y. &Sasisekharan, R.: Presents the novel observation that HSGAGs of differing. Structure can have opposing roles inmediating the processes of primary tumour growthand metastasis.
23. Blackhall, F. H., Merry, C. L., Davies, E. J. &Jayson, G. C.: Heparan sulfate proteoglycans and cancer.Br J. Cancer 85, 1094-1098 (2001).
24. Xiang, Y. Y, Ladeda, V. &Filmus, J.: Glypican-3 expression is silenced in human breast cancer.Oncogene20, 7408-7412(2001).
25. Filmus, J.: Glypicans in growth control and cancer.Glycobiology11, 19R-23R (2001).
26. Sanderson, R. D.: Heparan sulfate proteoglycans in invasion and metastasis.Semin. Cell Dev. Biol.12, 89-98 (2001).
27. Jayson, G. C.:Heparan sulfate undergoes specificstructural changes during the progression from humancolon adenoma to carcinomain vitro. J. Biol. Chem.273, 51-57 (1998).
28. DeBaun, M. R., Ess, J. &Saunders, S.: Simpson-Golabi-Behmel syndrome: progress towardunderstanding the molecular basis for overgrowth, malformation, and cancer predisposition.Mol. Genet.Metab.72, 279-286 (2001).
29. Mundhenke, C., Meyer, K., Drew, S. &Friedl, A.: Heparan sulfate proteoglycans as regulators of fibroblast growthfactor-2 receptor binding in breast carcinomas.Am. J.Pathol.160, 185-194 (2002).
30. Kreuger, J., Salmivirta, M., Sturiale, L., Gimenez-Gallego, G. &Lindahl, U.: Sequence analysis of heparan sulfate epitopeswith graded affinities for fibroblast growth factors 1 and 2. J. Biol. Chem.276, 30744-30752 (2001).
31. Iozzo, R. V. &San Antonio, J. D.: Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest.108, 349-355 (2001).
32. Folkman, J.: Angiogenesis-dependent diseases.Semin. Oncol.28, 536-542 (2001).
33. Sasisekharan, R., Moses, M. A., Nugent, M. A., Cooney, C. L. &Langer, R.: Heparinase inhibits neovascularization.Proc.Natl Acad. Scl. USA91, 1524-1528 (1994).
34. Karumanchi, S. A.:Cell surface glypicans are low-affinity endostatin receptors.Mol. Cell7, 811-822 (2001).
35. Smorenburg, S. M. &Van Noorden, C. J.: The complexeffects of heparins on cancer progression and metastasisin experimental studies.Pharmacol. Rev.53, 93-105(2001).
36. Tovari, J.:Role of sinusoidal heparan sulfate proteoglycan in liver metastasis formation.Int. J. Cancer71, 825-831 (1997).
37. Hulett, M. D.:Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.NatureMed.5, 803-809 (1999).
38. Vlodavsky, I.:Mammalian heparanase: gene cloning, expression and function in tumor progression andmetastasis.Nature Med.5, 793-802 (1999).
39. Vlodavsky, I.:These two studies report the cloning and characterization of the human heparanase gene.Heparanase is an enzyme that is produced by cancercells that was found to be a key factor or switch bywhich a tumour becomes metastatic. This has led to asubstantial effort to identify inhibitors of humanheparanase as a therapeutic strategy to combatmetastasis.
40. Kakkar, A. K. &Williamson, R. C.: Antithrombotic therapy in cancer.BMJ318, 1571-1572 (1999).
41. Zacharski, L. R. &Ornstein, D. L.: Heparin and cancer.Thromb. Haemost.80, 10-23 (1998).
42. Zacharski, L. R., Ornstein, D. L. &Mamourian, A. C.: Low-molecular-weight heparin and cancer.Semin. Thromb. Hemost.26, 69-77 (2000).
43. Zacharski, L. R., Ornstein, D. L. &Mamourian, A. C.: Definitive review of the effects of low-molecular-weight heparin on cancer progression.
44. Goger, B.:Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: amodel for chemokine regulation at inflammatory sites.Biochemistry 41, 1640-1646 (2002).
45. Koopmann, W., Ediriwickrema, C. &Krangel, M. S.: Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 p. J. Immunol.163, 2120-2127 (1999).
46. Vlodavsky, I.:Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development.Semin. Cancer Biol.12, 121-129 (2002).
47. Iversen, P. O., Sorensen, D. R. &Benestad, H. B.: Inhibitors of angiogenesis selectively reduce the malignant cell load inrodent models of human myeloid leukemias.Leukemia16, 376-381 (2002).
48. Parish, C. R., Freeman, C., Brown, K. J., Francis, D. J. &Cowden, W. B.: Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novelin vitroassays for angiogenesis and heparanase activity.Cancer Res.59, 3433-3441 (1999).
49. Bentolila, A.:Poly(N-acryl amino acids): a new class of biologically active polyanions.J. Med. Chem.43, 2591-2600 (2000).
50. Naggi, A.:Toward a biotechnological heparin through combined chemical and enzymatic modification of theEscherichia collK5 polysaccharide.Semin. Thromb.Hemost.27, 437-443 (2001).
51. Belting, M.: Tumor attenuation by combined heparan sulfate and polyamine depletion.Proc. Natl Acad. Sci. USA99, 371-376 (2002).
52. Merry, C. L., Lyon, M., Deakin, J. A., Hopwood, J. J. &Gallagher, J. T.: Highly sensitive sequencing of the sulfateddomains of heparan sulfate.J. Biol. Chem.274, 18455-18462 (1999).
53. Turnbull, J. E., Hopwood, J. J. &Gallagher, J. T.: A strategy for rapid sequencing of heparan sulfate and heparin saccharides.Proc. Natl Acad. Sci. USA 96, 2698-2703 (1999).
54. Vives, R. R.:Sequence analysis of heparan sulphate and heparin oligosaccharides.Biochem. J.339, 767-773(1999).
55. Venkataraman, G., Shriver, Z., Raman, R. &Sasisekharan, R.: Sequencing complex polysaccharides.Science 286, 537-542 (1999).
56. Keiser, N., Venkataraman, G., Shriver, Z. &Sasisekharan, R.: Direct isolation and sequencing of specific proteinbinding glycosaminoglycans.Nature Med.7, 123-128 (2001).
57. Borsig, L.: Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinomamucins, and tumor metastasis.Proc. Natl Acad. Sci. USA98, 3352-3357 (2001).
58. Petitou, M.:Experimental proof for the structure of a thrombin-inhibiting heparin molecule.Chemistry 7, 858-873(2001).
59. Ho, G., Broze, G. J. Jr. &Schwartz, A. L.: Role of heparan sulfate proteoglycans in the uptake and degradation oftissue factor pathway inhibitor-coagulation factor Xacomplexes.J. Biol. Chem.272, 16838-16844 (1997).
60. Nugent, M. A. &Iozzo, R. V.: Fibroblast growth factor-2.Int. J. Blochem. Cell Biol.32, 115-120 (2000).
61. Derksen, P. W.:Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotesMet signaling in multiple myeloma.Blood99, 1405-1410(2002).
62. Lin, X. &Perrimon, N. Dally cooperates withDrosophilaFrizzled 2 to transduce Wingless signalling.Nature400, 281-284 (1999).
63. Tsuda, M.:The cell-surface proteoglycan Dally regulates Wingless signalling inDrosophila.Nature400, 276-280 (1999).
64. Ma, Y. Q. &Geng, J. G. Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375cells to P-selectin under flow.J. Immunol.165, 558-565(2000).
65. Hoffman, M. P.:Cell type-specific differences in glycosaminoglycans modulate the biological activity of aheparin-binding peptide (RKRLQVQLSIRT) from the Gdomain of the laminin-a1 chain.J. Biol. Chem.276, 22077-22085 (2001).
66. Utani, A.:A unique sequence of the laminin-a 3G domain binds to heparin and promotes cell adhesionthrough syndecan-2 and -4.J. Biol. Chem.276, 28779-28788 (2001).
67. Lundmark, K.:Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate.J. CellPhysiol.188, 67-74 (2001).